摘要
目的:评价紫衫醇药涂球囊在下肢动脉硬化闭塞症腔内治疗中的有效性及安全性。方法:回顾性分析83例纳入股腘动脉闭塞病变临床试验的患者资料。结果:两组患者术前一般资料差异均无统计学意义(P>0.05);药涂球囊组(DCB组)平均靶病变血管长度(8.4±5.3)cm显著长于非药涂球囊组(UCB组)(8.0±4.3)cm(P<0.05);DCB组靶血管植入补救性金属裸支架率(23.6%)显著低于UCB组(42.6%)(P<0.01)。DCB组3、6及12个月一期通畅率均显著高于UCB组(P<0.01)。DCB组与UCB组患者均无随访期间死亡病例,UCB组目标肢体截肢率(7.1%)显著高于DCB组(0.0)(P<0.01)。结论:DCB在治疗下肢动脉硬化闭塞症病例临床疗效优于UCB,而且DCB治疗的安全性不劣于UCB。
Objective: To evaluate the efficacy and safety of the paclitaxel drug-coated balloon in the endovascular treatment of lower extremity arteriosclerosis obliterans. Methods: A retrospective analysis of 83 patients with clinical trials of femoral-popliteal artery occlusion disease was performed. Results:There was no statistically significant difference in preoperative data between the two groups (P >0.05). The average target lesion length (8.4±5.3)cm in the drug-coated balloon group(DCB group) was significantly longer than that in the uncoated balloon group (UCB group)(8.0±4.3)cm (P <0.05);the rate of target vessel implantation with remedial metal bare stent in DCB group (23.6%) was significantly lower than that in UCB group (42.6%)(P <0.01). The patency rates of the DCB group at 3, 6 and 12 months were significantly higher than those in the UCB group (P <0.01). No patients passed away during the follow-up period in the DCB group and the UCB group, and the target limb amputation rate in the UCB group(7.1%) was significantly higher than that in the DCB group (0.0%)(P <0.01). Conclusion: The clinical efficacy of DCB in the treatment of arteriosclerosis occlusions of lower limbs may be superior to UCB, and the safety of DCB treatment is not inferior to UCB.
作者
罗光泽
潘红瑞
朱杰昌
罗宇东
范海伦
冯舟
戴向晨
LUO Guang-ze;PAN Hong-rui;ZHU Jie-chang;LUO Yu-dong;FAN Hai-lun;FENG Zhou;DAI Xiang-chen(Department of Vascular Surgery,General Hospital,Tianjin Medical University,Tianjin 300052,China)
出处
《天津医科大学学报》
2019年第4期369-372,共4页
Journal of Tianjin Medical University
基金
天津市科技支撑重点项目基金资助(16YFZCSY01080)
关键词
下肢动脉硬化闭塞症
药涂球囊
紫杉醇
补救性支架
支架置入术
Lower extremity arterial occlusive disease
Drug-coated balloon angioplasty
Paclitaxel
Remedial stents
Stent imlantation
